Edition:
United States

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

524.65INR
5:24am EST
Change (% chg)

Rs2.95 (+0.57%)
Prev Close
Rs521.70
Open
Rs524.60
Day's High
Rs530.80
Day's Low
Rs520.50
Volume
2,230,338
Avg. Vol
3,139,691
52-wk High
Rs530.80
52-wk Low
Rs293.90

Chart for

About

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-India's Biocon To Transfer Biosimilar Business Via Slump Sale As 'Going Concern' To Biocon Biologics India

* INDIA'S BIOCON SAYS TO TRANSFER BIOSIMILAR BUSINESS THROUGH SLUMP SALE AS 'GOING CONCERN' TO BIOCON BIOLOGICS INDIA - EXCHANGES

Dec 07 2017

FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, making it the second copycat cancer drug to be approved in the United States.

Dec 01 2017

UPDATE 3-FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

* Approval ups confidence in Mylan's biosimilar efforts -analysts

Dec 01 2017

BRIEF-EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars

* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM

Nov 30 2017

BRIEF-Biocon ‍launches Krabeva in India​

* Launches Krabeva - biosimilar Bevacizumab for treating several types of cancer in India​

Nov 23 2017

BRIEF-Biocon says co's facility receives EIR with VAI status​

* Says ‍Biocon's facility receives EIR with vai status​ Source text for Eikon: Further company coverage:

Nov 19 2017

India's Biocon Q2 profit more than halves

Oct 26 India's Biocon Ltd posted a 53 percent fall in quarterly profit on Thursday, missing estimates, as higher costs at its Malaysia plant and pricing pressures in its active pharmaceutical ingredients business weighed.

Oct 26 2017

BRIEF-India's Biocon Sept-qtr consol profit more than halves

* Sept quarter consol profit 688 million rupees versus 1.47 billion rupees last year

Oct 26 2017

BRIEF-Biocon says US FDA completes inspection with no observations for Vishakhapatnam facility

* Says Biocon's facility in Vishakhapatnam completes USFDA inspection with no observations Source text for Eikon: Further company coverage:

Sep 18 2017

Samsung Bioepis wins EU endorsement for first Herceptin copy

* Bioepis could receive 4 EU biosimilar approvals in two years

Sep 15 2017

Earnings vs. Estimates

No consensus analysis data available.